These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21965724)

  • 1. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
    Wang H; Word BR; Lyn-Cook BD
    Anticancer Res; 2011 Oct; 31(10):3171-80. PubMed ID: 21965724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
    Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
    Jordheim LP; Dumontet C
    Biomark Med; 2013 Aug; 7(4):663-71. PubMed ID: 23905902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
    Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
    Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
    Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
    PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
    D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
    Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
    Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
    Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
    Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
    Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
    Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.
    Giovannetti E; Leon LG; Gómez VE; Zucali PA; Minutolo F; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):643-651. PubMed ID: 27906635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
    Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
    Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
    Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
    Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
    Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
    Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhu Y; Qi M; Lao L; Wang W; Hua L; Bai G
    Genet Test Mol Biomarkers; 2014 May; 18(5):306-12. PubMed ID: 24625353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
    Kawada N; Uehara H; Katayama K; Nakamura S; Takahashi H; Ohigashi H; Ishikawa O; Nagata S; Tomita Y
    J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):717-22. PubMed ID: 22426593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.